U.S. Markets close in 3 hrs 44 mins

Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

Stock Research Monitor: RXII, SAGE, and SGMO

LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration. This morning, WallStEquities.com recalls the previous performance of RXi Pharmaceuticals Corp. (NASDAQ: RXII), Sage Therapeutics Inc. (NASDAQ: SAGE), Sangamo Therapeutics Inc. (NASDAQ: SGMO), and Verastem Inc. (NASDAQ: VSTM). Companies in the Biotech industry have veryvolatileprofits. Many operate at a loss for many years until a highly profitable substance is manufactured - but when it does, their earnings can be even greater than those of pharmaceutical companies.All you have to do is sign up today for this free limited time offer by clicking the link below.


RXi Pharmaceuticals

Shares in Marlborough, Massachusetts headquartered RXi Pharmaceuticals Corp. saw a decline of 3.13%, ending Thursday's trading session at $1.86. The stock recorded a trading volume of 69,373 shares. The Company's shares are trading 20.27% below their 50-day moving average. Moreover, shares of RXi Pharmaceuticals, which focuses on discovering and developing immuno-oncology therapeutics to treat cancer, have a Relative Strength Index (RSI) of 32.97. Get the full research report on RXII for free by clicking below at:


Sage Therapeutics

Cambridge, Massachusetts headquartered Sage Therapeutics Inc.'s stock rose slightly by 0.06%, closing the day at $158.67 with a total trading volume of 236,018 shares. The Company's shares have advanced 2.97% in the past month, 7.65% in the previous three months, and 94.45% over the past year. The stock is trading 1.20% and 15.57% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 52.10.

On June 06th, 2018, research firm Ladenburg Thalmann initiated a 'Buy' rating on the Company's stock, with a target price of $230 per share.

On June 13th, 2018, Sage Therapeutics and Shionogi & Co., Ltd. announced that they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder and other indications in Japan, Taiwan, and South Korea. The goal of the collaboration is to accelerate development of a potentially groundbreaking medicine to patients in key Asian markets. Access the free research report on SAGE now by signing up at:


Sangamo Therapeutics

On Thursday, shares in Richmond, California headquartered Sangamo Therapeutics Inc. recorded a trading volume of 986,593 shares. The stock ended the day 1.31% higher at $15.50. The Company's shares have advanced 68.48% over the past year. The stock is trading below its 50-day moving average by 2.67%. Furthermore, shares of Sangamo Therapeutics, which focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy, have an RSI of 48.82.

On June 20th, 2018, research firm Bank of America/ Merrill initiated a 'Buy' rating on the Company's stock, with a target price of $24 per share.

On June 28th, 2018, Sangamo Therapeutics announced the appointment of Dr.Karen Smith, an accomplished drug development executive, to the Company's Board of Directors. Dr. Smith has over 20 years of biopharmaceutical industry experience inthe US, Europe, Canada, and Asia. Are you already registered with Wall St. Equities? Do so now for free, and get the report on SGMO at:



Needham, Massachusetts headquartered Verastem Inc.'s stock dropped 1.99%, finishing yesterday's session at $6.88 with a total trading volume of 986,536 shares. The Company's shares have surged 24.64% in the last month, 126.32% in the previous three months, and 183.13% over the past year. The stock is trading above its 50-day and 200-day moving averages by 22.06% and 67.15%, respectively. Additionally, shares of Verastem, which focuses on developing and commercializing drugs for the treatment of cancer, have an RSI of 55.24.

On July 02nd, 2018, Verastem announced that it will participate in the Oppenheimer Boston Oncology Insight Summit on July 10th and 11th, 2018 in Boston, Massachusetts. The two-day event will feature oncology-focused companies and will consist of one-on-one meetings with institutional investors preceded by a Lecture Series from members of the Whitehead Institute in Cambridge, Massachusetts. Aspiring Member, please take a moment to register below for your free research report on VSTM at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities